Home>R&D>Milestones

Milestones

12-2014 Fosun Pharma’s subsidiary Dongting Pharma obtained production license and a new drug certificate of escitalopram oxalate citalopram and tablets for treatment of depression, which is new products of category 3.1
12-2014 “Fosun Pharma 2020 Research and Innovation Plan” was issued at Fosun Pharma’s 20th anniversary celebration, the company would establish a Shanghai-centered global innovation R&D system, and strive to become a pharmaceutical enterprise with global R&D innovation capability
11-2014 Fosun Pharma’s subsidiary Shanghai Henlius submitted clinical application of monoclonal antibody agent Erbitux Biosimilar (for treating colorectal cancer) for registration
10-2014 the 11th joint packaging tablet of amodiaquine quinoline + compound sulfanilamide sheen (150 mg 25mg/500mg) (WHO reference number MA098) of Fosun Pharma’s subsidiary Guilin Pharma formally passed WHO-PQ certification
06-2014 “Industrial technology innovation strategic alliance of Fosun Pharma”,which is one of the “Industry-university-research Alliance” in National Science and Technology Major Project of the Ministry of Science and Technology of China successfully passed the acceptance
05-2014 artemether APIs passed the WHO PQ certification, creating the precedent for Guilin Pharma API PQ certification
05-2014 Fosun Pharma’s subsidiary Shanghai Henlius submitted clinical application of monoclonal antibody agent Herceptin Biosimilar (for treating gastric cancer) for registration
04-2014 Fosun Pharma obtained the exclusive license from Global TB Alliance for PA-824 drug
03-2014 Fosun Pharma’s subsidiary Shanghai Henlius obtained a clinical trial approval for rituximab Biosimilar for treating lymphoma
02-2014 Fosun Pharma won the Award for Science and Technology Innovation Enterprise of All-China Federation of Industry & Commerce
01-2014 Fosun Pharma’s subsidiary Chongqing Pharmaceutical Industry Research Institute obtained the first clinical trial approval for loxoprofen sodium gel for rheumatism and arthritis in China
11-2013 Fosun Pharma was identified as the first batch of national intellectual property advantage enterprises
10-2013 Fosun Pharma’s subsidiary Fochon Pharma signed a cooperation agreement with SELLAS Clinicals Holding AG on new drug development and licensing in Greece
10-2013 Fosun Pharma and Shanghai University of Traditional Chinese Medicine signed the cooperation agreement to establish a new Industry-university-research Alliance.
09-2013
08-2013
06-2013
03-2013
02-2013
01-2013
12-2012
12-2012
11-2012
11-2012
11-2012
07-2012
05-2012
09-2011
01-2011
11-2010
04-2010
02-2010
03-2009
12-2008
01-2008
08-2007
07-2006
05-2006
03-2006
12-2005
10-2005
10-2005
08-2003
01-2003
07-2002
06-2002
12-2001
09-2001
11-2000
12-1999
10-1999
12-1998
12-1998
11-1998
08-1998
01-1998
01-1998